CN109456974A - A kind of Endoglin aptamer and its application - Google Patents
A kind of Endoglin aptamer and its application Download PDFInfo
- Publication number
- CN109456974A CN109456974A CN201810708787.5A CN201810708787A CN109456974A CN 109456974 A CN109456974 A CN 109456974A CN 201810708787 A CN201810708787 A CN 201810708787A CN 109456974 A CN109456974 A CN 109456974A
- Authority
- CN
- China
- Prior art keywords
- endoglin
- sequence
- aptamers
- cell
- aptamer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
Abstract
The present invention discloses a kind of Endoglin aptamer and its application, belongs to genetic engineering, immunology and oncology technical field.The aptamers are one or several any sequence in nucleotide sequence shown in NO:1 ~ 5 SEQ ID.Aptamer of the present invention is obtained using full Cell depletion Cell-SELEX technology screening, molecular weight is smaller, it is readily synthesized and modifies, can high specific identification and high-affinity combination Endoglin, in conjunction with other cells not occurrence features, non-immunogenicity stablizes easily modification, convenient for synthesis and saves.The Endoglin detection kit and reagent paper prepared with the aptamers is high to Endoglin detection sensitivity, and is easy to optimize.It is applied in diagnosing tumor, tumor prognosis and the assessment of monitoring, diagnosing tumor.
Description
Technical field
The invention belongs to genetic engineering, immunology and oncology technical field, in particular to a kind of Endoglin nucleic acid is suitable
Ligand and its application.
Background technique
Tumor vascular endothelial cell is the basis of Tumor Angiongesis, has very important work to tumour growth and transfer
With.Early diagnosis of tumor and treatment are carried out for tumor vascular endothelial cell, it has also become tumour correlative study development necessarily becomes
Gesture.Endoglin is a kind of transmembrane glycoprotein on tumor vascular endothelial cell surface, in the vascular endothelial cell of active proliferation
It is overexpressed, and does not express in normal vascular endothelia cell or weak expression.Therefore, Endoglin is acknowledged as Tumor Angiongesis
The specific marker formed with new vessels.
Aptamer is that one kind can have and anti-with the DNA or RNA sequence in conjunction with target molecule high specific high-affinity
The similar effect of body, commonly referred to as " chemical antibody ".In recent years, with the continuous development of aptamer screening technique, more
It is found come more tumor associated nucleic acid aptamers sequences by people.However, the relevant aptamer of these tumours is usually
It is only capable of identifying a kind of tumour cell or a kind of tumour, largely limits the application of aptamer.Currently, can specific target
It not yet appears in the newspapers to the screening of tumor vascular aptamers.
Summary of the invention
In view of the deficiencies of the prior art, the present invention provides a kind of Endoglin aptamer and its applications.
Technical solution used in purpose to realize the present invention are as follows:
A kind of Endoglin aptamer, the aptamers are in nucleotide sequence shown in NO:1 ~ 5 SEQ ID
One or several any sequence.
Preferably, the aptamers have with any one in nucleotide sequence shown in NO:1 ~ 5 SEQ ID or
The sequence that the homology of several sequences is 60% or more.
Preferably, the aptamers have with any one in nucleotide sequence shown in NO:1 ~ 5 SEQ ID or
The sequence that several sequences are hybridized.
Preferably, the aptamers have with any one in nucleotide sequence shown in NO:1 ~ 5 SEQ ID or
The sequence that several sequences are transcribed.
Preferably, several positions in the aptamers sequence be phosphorylated, methylate, amination, sulfhydrylation or
Isotopologue.
Preferably, it is combined with biotin in the aptamers sequence, digoxin, fluorescent material, nano luminescent material, gathers
Ethylene glycol, peptide fragment, albumen, folic acid or enzyme label.
Preferably, the Endoglin aptamer have in nucleotide sequence shown in NO:1 ~ 5 SEQ ID
One or several any sequence alterations at corresponding peptide nucleic acid.
The present invention also provides a kind of Endoglin aptamers in preparation Endoglin detection kit or detection reagent
The application of paper.
The application uses Cell-SELEX screening technique in the selection of screening technique.Although target molecules Endoglin
For a kind of cell membrane surface protein, and traditional protein screening technique is not used, but uses Cell-SELEX screening technique, and
The 293T cell line (293T-hE) of artificial constructed stable expression target molecules Endoglin is as positive screening cell.This method has
Effect avoids the difference of external synthetic protein Yu epicyte protein native conformation, while also solving target cell and obtaining and being stranded
Difficult problem.In addition, the positive and reverse screening cell that the present invention selects only has the differential expression of the single molecule of Endoglin, this makes
Aptamers obtained are screened with more accurate targeting, target spot confirmation required when subsequent screening is completed is simplified and investigates
Etc. correlation steps, optimize experimental arrangement.The stage is investigated in the verifying of candidate aptamers, the aptamers that the present invention obtains can also be with
Other cells (such as HUVEC cell) with Endoglin expression other than target cell combine, and this demonstrates the present invention to screen
Method is practical.
Present invention substantive distinguishing features outstanding and significant progress are:
Aptamer of the present invention using full bacterium abatement Cell-SELEX technology screening and obtain, molecular weight is smaller, be readily synthesized and
Modification, can high specific identification and high-affinity combination Endoglin, with other bacteriums not occurrence features ining conjunction with, nothing be immunized
Originality stablizes easily modification, convenient for synthesis and saves, can be used for detecting Endoglin, and effectively prevents and control
Endoglin infection is of great significance.The Endoglin detection kit and reagent paper pair prepared with the aptamers
Endoglin detection sensitivity is high, and is easy to optimize.
Detailed description of the invention
Fig. 1 is to be enriched with library for 293T-hE cell and 293T cell combination ability flow cytometer detection as a result, A:293T-hE is thin
Cellular surface fluorescence intensity increases with number of screening round and is gradually increased, and B:293T cell surface fluorescence intensity increases with number of screening round and becomes
Change not significant.
Fig. 2 is candidate aptamers and 293T-hE cell combination fluorescence imaging result (400x).
Fig. 3 is each aptamers truncated sequence situation streaming result in conjunction with target cell.
Fig. 4 is aptamer ENG-4c living imaging result in Mice Body.
Specific embodiment
The present invention program is described in further detail below with reference to embodiment, following the description is merely to explain this hair
It is bright, its content is not defined.
Embodiment
Aptamers screening process is that duplicate, progressive process is taken turns one more, any one link mistake occurs all by shadow
Ring to the end as a result, even resulting in entire the failure of an experiment when serious.Therefore, before in accordance with basic Cell-SELEX screening step
It puts, it is also noted that the control of details, to improve the screening efficiency of aptamers.Specifically to follow following some points for attention:
(1) guarantee cell state
Whether aptamers screening is successful to have very close relationship with cell state.Cell state may will affect it when poor
The normal expression of surface protein, leads to the missing or change of expected aptamers target, to influence the progress of aptamers screening.This
Two groups of positive and reverse screening cells that invention is selected are both attached cells of 293T-hE and 293T respectively.Before each screening,
It need to guarantee two kinds of cell culture times within 24-48 h, to may cause cell adherent not yet this is because incubation time is too short
Reach perfect condition, and the too long cell that may cause of incubation time is adherent excessively securely, the link for scraping off cell and collecting compared with
For difficulty.In addition, cell also should be at growing logarithmic growth phase the most vigorous, and maintain vigour greater than 90%.Cell viability
Judgement is mainly to carry out according to trypan blue negative staining method, when cell activity is preferable, will not still can under mirror by Trypan Blue
Observe the good cell of translucency；When cell is dyed to blue as the result is shown under the microscope, prompt cell state poor, very
To death.
(2) selection of temperature is screened
Temperature can usually generate certain influence to the combination of cell and DNA.Therefore, suitable temperature is selected to screen aptamers
Success or not plays important decisive action.The screening selection that the present invention is carried out carries out under 4 °C of environment, this is because with
The extension of time can generate endocytosis to DNA in (such as 37 °C) cell under hot environment, affect the rich of library to a certain extent
Fu Xing.And reduction screening temperature appropriate can effectively avoid this phenomenon.
(3) it is actively introduced counter-selection
To obtain the aptamers having compared with high specific as early as possible, it should counter-selection choosing be added before the 3rd wheel as far as possible.In the present invention,
Anti- screening step is added in front of each round just screens, can not will directly select the DNA of cell combination to collect simultaneously with counter-selection in this way
It puts into positive screening cell, without carrying out other washing steps, avoids screening while simplifying screening step
The partial loss in library.
(4) increase of screening pressure
With the increase of number of screening round, it to be gradually increased screening pressure, can just effectively improve screening efficiency and success rate.Screening pressure
The increase of power is mainly reflected in wash time, washing times, incubation time etc..It specifically, is exactly with number of screening round
Increase, extend counter-selection as one sees fit and select the incubation time of cell and DNA library so that counter-selection choosing carry out more completely so that literary
The poor DNA removal of specificity is more thorough in library；It reduces the dosage of DNA library simultaneously and is incubated for it with positive sieve cell
Time shortens, and washing intensity increases.The screening efficiency of aptamers not only can be improved in this way, moreover it is possible to obtain screening suitable
Ligand has more preferably binding ability.It is as shown in table 1 to the specific detail of the regulation of screening pressure herein.
1 screening pressure of table regulates and controls detail list
| Number of screening round | Library dosage (pmol) | Positive sieve culture dish specification (mm) | Positive sieve incubation time (min) | Counter-selection culture dish specification (mm) | Counter-selection incubation time (min) | Washing buffer volume (mL) |
| 1 | 5000 | 10 | 60 | - | - | 2 |
| 2 | 278 | 10 | 60 | - | - | 2 |
| 3 | 289 | 10 | 55 | - | - | 2 |
| 4 | 345 | 10 | 55 | 6 | 30 | 2 |
| 5 | 336 | 10 | 50 | 6 | 30 | 3 |
| 6 | 356 | 10 | 50 | 6 | 35 | 3 |
| 7 | 340 | 6 | 45 | 6 | 35 | 3 |
| 8 | 320 | 6 | 45 | 6 | 40 | 3 |
| 9 | 300 | 6 | 40 | 6 | 40 | 4 |
| 10 | 280 | 6 | 40 | 10 | 45 | 4 |
| 11 | 260 | 6 | 35 | 10 | 45 | 4 |
| 12 | 240 | 6 | 35 | 10 | 50 | 4 |
| 13 | 220 | 6 | 30 | 10 | 50 | 5 |
| 14 | 200 | 6 | 30 | 10 | 55 | 5 |
| 15 | 200 | 6 | 30 | 10 | 55 | 5 |
| 16 | 200 | 6 | 30 | 10 | 60 | 5 |
| 17 | 200 | 6 | 30 | 10 | 60 | 5 |
| 18 | 200 | 6 | 30 | 10 | 60 | 5 |
| 19 | 200 | 6 | 30 | 10 | 60 | 5 |
1. screening conditions selection and optimization
Screening process is constituted by repeating PCR process, and the selection of PCR condition is of crucial importance the selection result, PCR
Condition selection fault usually makes amplified production have more nonspecific products, may cause screening when serious and loses completely
It loses.Therefore, before being screened, the various aspects such as annealing temperature, thermal cycle number need to be optimized, to obtain optimal PCR
Condition.
2. screening library enrichment degree to determine
To judge screening process of the invention, i.e., as number of screening round increases, the richness of the ssDNA in conjunction with target cell 293T-hE
Collect situation, 12 wheels, 15 wheels, 17 wheels, 19 wheel screening products use simultaneously with the PCR amplification of FITC fluorescent marker
Initial libraries with FITC label carry out Flow cytometry or fluorescence microscope image checking as negative control.Together
When use counter-selection to select cell 293T as control cell.Experimental result as shown in Figure 1, with number of screening round increase, screening text
Fluorescence curve of the library in conjunction with target cell 293T-hE gradually deviates to the right, indicates gradually increasing for fluorescence intensity.By in figure
As can be seen that the degree that this fluorescence curve deviates to the right is gradually increased with the progress of screening, and reach in 17 wheel
Peak.The degrees of offset of former wheels is compared therewith, and fluorescence curve of the 19 wheel screening products in conjunction with target cell is bent compared with 17 wheel fluorescence
There was only faint degrees of offset for line, such phenomenon is exactly the mark of library enrichment degree judgement, this prompt screening library is rich
Collection degree has reached saturation state substantially.And the fluidic cell after being incubated for each round screening library and control cell 293T
In the detected result of art, the shift phenomenon of this fluorescence curve is not observed.And with number of screening round into
Row, the detected fluorescence curve of counter-selection cell flow cytometry only have extremely faint right side degrees of offset.This is likely to only
Certain non-specific adsorption for being only because DNA sequence dna and cell surface causes.The above results not only confirm that screening has reached
Terminal, have also demonstrated the counter-selection choosing enrichment library that plays preferable effect really, therefore obtain being added in the present invention only with target
Cell has stronger combination, and can hardly be in conjunction with control cell.
In order to carry out more intuitive observation, and the method for using cell climbing sheet to this fluorescence intensity change, use
Fluorescence microscope investigates 19 wheel libraries with the case where positive and reverse screening cell incubation.As a result as shown in Fig. 2, fluorescence microscopy
In mirror image, the visible obvious green fluorescence expression in the periphery target cell 293T-hE, and shown after light field picture is superimposed with fluorescence picture
And cell membrane surface protein show, the distributing position of these green fluorescences meets design of the invention about around cell membrane, i.e.,
It combines.Conversely, can not observe green florescent signal on the surface of control cell 293T, it was demonstrated that 19 wheel libraries cannot with it is right
Photo cell combines.Both the above laboratory facilities it can be proved that this screen it is obtained 19th wheel library can specificity
With expression Endoglin positive cell 293T-hE combine, without with negative control cell 293T cell combination.
3 sequencing result secondary structure analysis
Since aptamers function in conjunction with target cell, the secondary structure of DNA sequence dna is depended greatly on, therefore,
While investigating primary structure homology, the mould of secondary structure situation has been carried out to each family's DNA sequence dna using NUPACK
Quasi-, simulated environment selects combination buffer condition, i.e. monovalent cation concentration is 150 mM, and divalent cation concentration is 4 mM,
Temperature is 4 °C.The results show that the aptamers sequence of each family has the same or similar secondary structure mostly, therefore select
It is glimmering to carry out FITC as candidate aptamers for the higher aptamers sequence of representative or frequency of occurrence in each family
The candidate aptamers sequent synthesis of signal.Specific candidate's aptamers sequence is shown in Table 2.
The candidate aptamers sequence of table 2 and its equilibrium dissociation constant
| Title | Sequence (5 ' -3 ') | Kd (nM) |
| ENG-1 | GAATTCAGTCGGACAGCGACGCAAGGATAGTAATTAGGTTTGGTGCGGTGGGGTAATTTCAGCGATGGACGAATATCGTCTCCC | 46.79 ± 27.15 |
| ENG-2 | GAATTCAGTCGGACAGCGGAGAATGGCGTTAAGCTTTTCTTCCCTTGTGTTTGATTCTTAACCGATGGACGAATATCGTCTCCC | 81.99 ± 26.93 |
| ENG-3 | GAATTCAGTCGGACAGCGTATTACAAGGCTCTCAGCCGAGCGGCCCCGGCTCCTAGGGGAATAGATGGACGAATATCGTCTCCC | 52.30 ± 46.78 |
| ENG-4 | GAATTCAGTCGGACAGCGGATCAGTTTTCCATGCCAGTTGGTATTCCGCGACAGTTTGATCTCGATGGACGAATATCGTCTCCC | 5.58 ± 3.11 |
| ENG-5 | GAATTCAGTCGGACAGCGCAGTAATCCCTTGTGTTTGATGCTCATTTCTCTCTGAAATTGCTCGATGGACGAATATCGTCTCCC | 38.52 ± 19.72 |
The design of 4 ENG-4 optimizations
The above confirms that the present invention screens the aptamers ENG-4 obtained in numerous aptamers candidate sequences with most strong
Combination, therefore it can be expected that its in tumor associated target from now on to playing certain effect in Clinics and Practices.However,
Identical as initial libraries, ENG-4 is the DNA sequence dna with 84 bp length, and in various functional studies, DNA sequence dna
Length is longer, and stability is also poorer.Moreover, reasonably removal aptamers sequence in it is certain do not function, even because
Space occupy-place and influence aptamers play combination base sequence, it is most important to the acquisition of more excellent aptamers.Therefore, originally
Invention further carries out sequence optimisation to ENG-4, and this optimization is main by the way of sequence truncation, i.e., draws former sequence both ends
Object carries out all or part of removal.Each aptamers sequence is as shown in table 3 after optimization truncates.
3 ENG-4 of table optimizes truncated sequence
| Title | Sequence (5 ' -3 ') |
| ENG-4 | GAATTCAGTCGGACAGCGGATCAGTTTTCCATGCCAGTTGGTATTCCGCGACAGTTTGATCTCGATGGACGAATATCGTCTCCC |
| ENG-4a | GATCAGTTTTCCATGCCAGTTGGTATTCCGCGACAGTTTGATCTCGATGGACGAATATCGTCTCCC |
| ENG-4b | GAATTCAGTCGGACAGCGGATCAGTTTTCCATGCCAGTTGGTATTCCGCGACAGTTTGATCTC |
| ENG-4c | GATCAGTTTTCCATGCCAGTTGGTATTCCGCGACAGTTTGATCTC |
5 ENG-4 optimization binding abilities are investigated
Flow cytometry is carried out to ENG-4 optimization, investigates the combination situation of itself and target cell 293T-hE.As a result such as
Shown in Fig. 3, compared with former sequence, ENG-4a and ENG-4b have a partial reduction for the binding ability of target cell, and ENG-4c
It is not substantially change with the binding ability of target cell.The results show that the aptamers sequence that the present invention obtains is playing combination
When effect, forward and reverse primer sequence may be not rely on, thus after eliminating forward and reverse primer at both ends, have compared with
The ENG-4c of short length also can play good combination with target cell 293T-hE.And compared with former sequence, truncated sequence
ENG-4c can improve to a certain extent stability and avoid the ability being degraded since length shortens, thus may be subsequent
More outstanding Targeting Effect is played in invention.
12 living imaging results
To investigate the targeting that the obtained aptamer ENG-4c of this screening is directed to tumor by local among complex environment in vivo
Effect, the present invention investigate it using mouse living imaging method.In A549 Pulmonary carcinoma nude mice Transplanted tumor model living imaging
In experiment, is injected through tail vein to tumor bearing nude mice have the random sequence of CY5 fluorescent marker and with CY5 label respectively
ENG-4c aptamers, control group are injected PBS, are shot after 1h.As a result as shown in figure 4, the random sequence marked in CY5
In group, fluorescence can not be enriched in nude mouse tumor part, but be enriched among liver and be metabolized, this shows random sequence
Do not have targeting to tumor by local；In the ENG-4c aptamers group of CY5 label, fluorescence is enriched in tumor by local mostly,
Only small part is metabolized among liver, this shows in complicated biological vivo environment, what the present invention screened
ENG-4c has good targeting for tumour；In PBS control group, any luciferase expression is not observed.The above reality
Test the result shows that, the aptamers ENG-4c screened target in vivo in there is good effect, there is potential application
Value.
The foregoing is only a preferred embodiment of the present invention, is not intended to restrict the invention, for the skill of this field
For art personnel, the invention may be variously modified and varied.It is done within the spirit and principles of the present invention any to repair
Change, equivalent replacement, improvement etc., should be included within scope of the invention.
Sequence table
<110>Guangxi Medical University
<120>a kind of Endoglin aptamer and its application
<141> 2018-07-02
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 84
<212> DNA
<213>artificial sequence (Artificial sequence Latin)
<400> 1
gaattcagtc ggacagcgac gcaaggatag taattaggtt tggtgcggtg gggtaatttc 60
agcgatggac gaatatcgtc tccc 84
<210> 2
<211> 84
<212> DNA
<213>artificial sequence (Artificial sequence Latin)
<400> 2
gaattcagtc ggacagcgga gaatggcgtt aagcttttct tcccttgtgt ttgattctta 60
accgatggac gaatatcgtc tccc 84
<210> 3
<211> 84
<212> DNA
<213>artificial sequence (Artificial sequence Latin)
<400> 3
gaattcagtc ggacagcgta ttacaaggct ctcagccgag cggccccggc tcctagggga 60
atagatggac gaatatcgtc tccc 84
<210> 4
<211> 84
<212> DNA
<213>artificial sequence (Artificial sequence Latin)
<400> 4
gaattcagtc ggacagcgga tcagttttcc atgccagttg gtattccgcg acagtttgat 60
ctcgatggac gaatatcgtc tccc 84
<210> 5
<211> 83
<212> DNA
<213>artificial sequence (Artificial sequence Latin)
<400> 5
gaattcagtc ggacagcgca gtaatccctt gtgtttgatg ctcatttctc tctgaaattg 60
ctcgatggac gaatatcgtc tcc 83
Claims (9)
1. a kind of Endoglin aptamer, which is characterized in that the aptamers are core shown in NO:1 ~ 5 SEQ ID
One or several any sequence in nucleotide sequence.
2. Endoglin aptamer according to claim 1, which is characterized in that the aptamers have and SEQ
The sequence that the homology of one or several any sequence in nucleotide sequence shown in NO:1 ~ 5 ID is 60% or more.
3. Endoglin aptamer according to claim 1, which is characterized in that the aptamers have and SEQ
The sequence that one or several any sequence in nucleotide sequence shown in NO:1 ~ 5 ID is hybridized.
4. Endoglin aptamer according to claim 1, which is characterized in that the aptamers have and SEQ
The sequence that one or several any sequence in nucleotide sequence shown in NO:1 ~ 5 ID is transcribed.
5. Endoglin aptamer according to claim 1, which is characterized in that the aptamers have and SEQ
One or several any sequence in nucleotide sequence shown in NO:1 ~ 5 ID optimizes truncated sequence.
6. Endoglin aptamer according to claim 1, which is characterized in that if in the aptamers sequence
A dry position be phosphorylated, methylate, amination, sulfhydrylation or isotopologue.
7. Endoglin aptamer according to claim 1, which is characterized in that combined in the aptamers sequence
There are biotin, digoxin, fluorescent material, nano luminescent material, polyethylene glycol, peptide fragment, albumen, folic acid or enzyme label.
8. Endoglin aptamer according to claim 1, which is characterized in that the Endoglin nucleic acid adaptation
Body have with one or several any sequence alterations in nucleotide sequence shown in NO:1 ~ 5 SEQ ID at corresponding peptide core
Acid.
9. Endoglin aptamer described in claim 1-7 any one is in preparation Endoglin detection kit or detection
The application of reagent paper.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810708787.5A CN109456974A (en) | 2018-07-02 | 2018-07-02 | A kind of Endoglin aptamer and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810708787.5A CN109456974A (en) | 2018-07-02 | 2018-07-02 | A kind of Endoglin aptamer and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109456974A true CN109456974A (en) | 2019-03-12 |
Family
ID=65606270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810708787.5A Withdrawn CN109456974A (en) | 2018-07-02 | 2018-07-02 | A kind of Endoglin aptamer and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109456974A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109576273A (en) * | 2018-07-03 | 2019-04-05 | 广西医科大学 | A set of tumor-marker molecular nucleic acid aptamers and application based on CRISPR/Cas9 |
| CN114149941A (en) * | 2021-10-29 | 2022-03-08 | 上海交通大学医学院附属仁济医院 | Bacterium with surface combined with targeting ligand and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1911959A (en) * | 1998-10-09 | 2007-02-14 | 希龙公司 | Neisseria genomic sequences and their use |
| CN104364375A (en) * | 2012-06-04 | 2015-02-18 | 日本电气方案创新株式会社 | Nucleic acid molecule binding to influenza virus and use therefor |
| WO2017031169A1 (en) * | 2015-08-17 | 2017-02-23 | The Johns Hopkins University | Mesenchymal cell-binding composite material for tissue restoration |
| CN107029252A (en) * | 2017-04-06 | 2017-08-11 | 广西医科大学 | The preparation method of one species specificity magnetic Endoglin aptamers imaging needle probe systems |
| CN107198779A (en) * | 2016-11-29 | 2017-09-26 | 南京东纳生物科技有限公司 | A kind of nanometer coupled complex of stem cell labeling spike and targeting navigation and its preparation method and application |
-
2018
- 2018-07-02 CN CN201810708787.5A patent/CN109456974A/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1911959A (en) * | 1998-10-09 | 2007-02-14 | 希龙公司 | Neisseria genomic sequences and their use |
| CN104364375A (en) * | 2012-06-04 | 2015-02-18 | 日本电气方案创新株式会社 | Nucleic acid molecule binding to influenza virus and use therefor |
| WO2017031169A1 (en) * | 2015-08-17 | 2017-02-23 | The Johns Hopkins University | Mesenchymal cell-binding composite material for tissue restoration |
| CN107198779A (en) * | 2016-11-29 | 2017-09-26 | 南京东纳生物科技有限公司 | A kind of nanometer coupled complex of stem cell labeling spike and targeting navigation and its preparation method and application |
| CN107029252A (en) * | 2017-04-06 | 2017-08-11 | 广西医科大学 | The preparation method of one species specificity magnetic Endoglin aptamers imaging needle probe systems |
Non-Patent Citations (5)
| Title |
|---|
| HUIHUI YAN等: "Imaging Tiny Hepatic Tumor Xenografts via Endoglin-Targeted Paramagnetic/Optical Nanoprobe", 《ACS APPL. MATER. INTERFACES》 * |
| JUNTAO TAN等: "A New Theranostic System Based on Endoglin Aptamer Conjugated Fluorescent Silica Nanoparticles", 《THERANOSTICS》 * |
| KETAI GUO等: "Aptamer‐based capture molecules as a novel coating strategy to promote cell adhesion", 《J. CELL. MOL. MED.》 * |
| 王雨晴: "Endoglin适配体筛选鉴定与体内成像研究", 《中国优秀硕士学位论文全文库》 * |
| 金征宇等: "《基因与纳米探针-医学分子成像理论与实践 上》", 30 November 2017 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109576273A (en) * | 2018-07-03 | 2019-04-05 | 广西医科大学 | A set of tumor-marker molecular nucleic acid aptamers and application based on CRISPR/Cas9 |
| CN114149941A (en) * | 2021-10-29 | 2022-03-08 | 上海交通大学医学院附属仁济医院 | Bacterium with surface combined with targeting ligand and application thereof |
| CN114149941B (en) * | 2021-10-29 | 2023-09-19 | 上海交通大学医学院附属仁济医院 | Bacteria with surface combined with targeting ligand and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xia et al. | Identification of a cell-of-origin for fibroblasts comprising the fibrotic reticulum in idiopathic pulmonary fibrosis | |
| CN102498211B (en) | Nucleic acid aptamer specifically binding to pancreatic cancer cells or tissues and use thereof | |
| CN103205431B (en) | Nucleic acid aptamer and derivatives thereof, screening method of nucleic acid aptamer, application of nucleic acid aptamer and derivatives in detecting human biliary duct carcinoma cell line | |
| CN108034658A (en) | A kind of aptamer for detecting people's uveal melanoma cells | |
| CN105385691B (en) | For detecting the aptamer and detection kit of people's height transfer colon cancer cell line LoVo | |
| CN103387988A (en) | Aptamer EpCAM (epithelial cell adhesion molecule) Ccut of EpCAM and preparation method thereof | |
| CN109576274A (en) | A kind of Endoglin aptamer and application based on CRISPR/Cas9 | |
| CN102766693B (en) | Nucleic acid aptamer for detecting human hepatoma cell line SMMC-7721 as well as screening method and application thereof | |
| CN104498500B (en) | A kind of aptamer for identifying adriamycin-resistant breast cancer cell and its screening technique and application | |
| CN106191069A (en) | A kind of aptamer sequence identifying and combine human TfR and application thereof | |
| CN109456974A (en) | A kind of Endoglin aptamer and its application | |
| van Tienderen et al. | Extracellular matrix drives tumor organoids toward desmoplastic matrix deposition and mesenchymal transition | |
| US10837964B2 (en) | DNA aptamer binding to cancer cell | |
| CN106916821A (en) | A kind of ssDNA aptamers and its application | |
| CN101143895B (en) | Polypeptide with tumour targeting effects and preparation method thereof | |
| CN109576272A (en) | A kind of DKK-1 aptamer and its application | |
| CN106636317A (en) | Lung cancer related mciroRNA detection kit | |
| CN109576273A (en) | A set of tumor-marker molecular nucleic acid aptamers and application based on CRISPR/Cas9 | |
| Kanayasu‐Toyoda et al. | Occludin as a functional marker of vascular endothelial cells on tube‐forming activity | |
| CN101768210A (en) | Tumor targeting polypeptide and preparation method thereof | |
| CN106282194B (en) | Breast cancer lines specific nucleic acid aptamers and its application in preparation detection, diagnosing and treating human breast carcinoma preparation | |
| CN109628455A (en) | A kind of aptamer detecting human colon carcinoma and its application in preparation detection preparation | |
| CN113373153A (en) | Aptamer ZQ-2 targeting human highly invasive choroidal melanoma and application | |
| CN113337511A (en) | Aptamer QQ-4 targeting human highly invasive choroidal melanoma and application | |
| CN113373154A (en) | Aptamer PZ-1 targeting human highly invasive choroidal melanoma and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190312 |
|
| WW01 | Invention patent application withdrawn after publication |